Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01066897 · ClinicalTrials.gov registry record · Phase 4
Imaging the Nucleus Accumbens in Major Depressed Patients 'Treated With Pramipexole
A Phase 4 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
NCT01066897: Clinical Trial Phase 4 study, sponsored by Stanford University.
NCT01066897 is a Phase 4 study that was terminated before completion, run by Stanford University. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01066897, a Phase 4 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
Study Summary
We hope to learn how a brain circuit that is important to the understanding of depression, anhedonia and positive affect responds to a novel pharmaceutical treatment for depression and related symptoms. Adults who have a diagnosis of major depression and are not completely responsive to antidepressant medication will be sought out for participation; as will an equal number of adults not suffering from the disorder. Those suffering from depression will be given pramipexole, an investigational medication for eight weeks during which information will be collected about mood, cognition, and brain function. Adults not suffering from depression will also be evaluated with these measures.
Interventions
- DRUG Pramipexole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2010-02 |
| Est. Completion | 2013-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01066897
The ClinicalTrials.gov registry entry for NCT01066897 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pramipexole is the first listed.
NCT01066897 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01066897 about?
NCT01066897 is a clinical study titled "Imaging the Nucleus Accumbens in Major Depressed Patients 'Treated With Pramipexole". We hope to learn how a brain circuit that is important to the understanding of depression, anhedonia and positive affect responds to a novel pharmaceutical treatment for depression and related symptoms. Adults who have a diagnosis of major depression and are not completely responsive to antidepressa...
What is the current status of trial NCT01066897?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2010-02. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01066897?
The interventions under investigation include: Pramipexole (DRUG).
Who is sponsoring clinical trial NCT01066897?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.